ASCO 2015 | HELIOS trial: Ibrutinib for relapsed/refractory chronic lymphocytic leukemia

Jacqueline Barrientos

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of the North Shore-LIJ Cancer Institute, Lake Success, NY, provides a summary of the progression-free survival results of the phase 3 HELIOS trial, which evaluated ibrutinib in combination with bendamustine and rituximab for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.

Share this video